期刊
FEBS LETTERS
卷 583, 期 7, 页码 1164-1170出版社
WILEY
DOI: 10.1016/j.febslet.2009.03.005
关键词
Osteoclast; Lyn; RANKL
资金
- 21C Frontier Functional Proteomics Project [FPR08B1-170]
- New Drug Target Discovery [M10748000257-07N4800-25710]
- Science Research Center [R11-2008-023-01001-0]
Osteoclasts differentiate from macrophage-lineage cells to become specialized for bone resorption function. By a proteomics approach, we found that Lyn was down-regulated by the osteoclast differentiation factor, receptor activator of NF-kappa B ligand (RANKL). The forced reduction of Lyn caused a striking increase in the RANKL-induced PLC gamma 1, Ca2+, and NFATc1 responses during differentiation. These data suggest that Lyn plays a negative role in osteoclastogenesis by interfering with the PLC gamma 1-mediated Ca2+ signaling that leads to NFATc1 activation. Consistent with the in vitro results, in vivo injection of Lyn specific siRNA into mice calvariae provoked a fulminant bone resorption. Our study provides the first evidence of the involvement of Lyn in the negative regulation of osteoclastogenesis by RANKL. (C) 2009 Federation of European Biochemical Societies. Published by Elsevier B. V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据